Neurocrine: FDA accepts sNDA for valbenazine

Neurocrine Biosciences announced that the U.S. FDA has accepted its supplemental New Drug Application for valbenazine as a treatment for chorea associated with Huntington disease. The agency set a Prescription Drug User Fee Act target action date of August 20, 2023.